Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (2653)	10/19/1998 6:58:00 AM
From: EPS	Read Replies (1) \| Respond to of 3702

I heard that discussing ideas is the purpose of SI. Especially it's annoying when people just tell me what I write is nonsense with no reasoning to back up their comment. I'm sorry you don't see the reasoning behind my arguments. TSRG was valued at 7/8 with PE = $/infinity$. A few months after a 4 to 1 reverse split it is valued at 7/8 with same PE. The markets just don't follow suit... Don't be fooled in believing that just because you are against the rest of the world it necessarily follows that you are right. Reverse splits with no earnings in sight and no change in the story of the company is just simply not a sound idea. If the problem is listing or such there are other methods available...But then I think the energy should be spent improving the research and the management of the operation so that it really becomes viable. Artificial valuations are very hard to sustain. Victor, 1998 PS 1984 was a wonderful year.

To: Maurice Winn who wrote (2653)	11/7/1998 8:38:00 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3702

Maurice:Here is a chance to put your 10 points theory of "Advantages of Reverse Split" to a test. Buy Cytel (CYTL) presently around $0.50 to $0.60. They just announced a one for seven reverse split. That will bring the number of shares down to 5 million. They still have a majority ownership of Epimmune which just received INH funds for they research on vaccine for hepatitis-C. Also working with Monsanto's Searle on a cancer vaccine. In the mean time TCLN has bounced back from October's 9th and 13th lows of $0.63 and yesterday's close of $1.09 brought the price above the 40 day average line (now at 1.00) If we can overcome the resistance at $1.30- $1.60 level we should be testing September's 15th high of $2.00.Even without a reverse split!! The chart is starting to look better.(By the way yesterday's price was also just above the 25 week average line.) Good luck to all. Bernard